Search - tctmd.com

Displaying 61 - 80 of 129

Sort: Relevancy | Date

Takotsubo Rising During COVID-19? Stress, Viral Triggers Need Attention

News Daily News

Takotsubo Rising During COVID-19? Stress, Viral Triggers Need Attention

Yael L. Maxwell

May 08, 2020

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

News Daily News

ACE Inhibitors/ARBs Safe, Possibly Protective in Hypertensive COVID-19 Patients

April 24, 2020

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

April 21, 2020

COVID-19 Linked to 38% Drop in US STEMIs

News Daily News

COVID-19 Linked to 38% Drop in US STEMIs

April 10, 2020

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

News Daily News

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

April 10, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

News Daily News

Cardiac Injury in COVID-19 Sharply Increases Risk of Death

March 26, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

News Opinion Editor's Corner

A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out

March 16, 2020

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

News Daily News

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Michael O'Riordan

March 11, 2020

First Point-of-Care hs-Troponin I Assay Matches Lab-Based Tests

News Daily News

First Point-of-Care hs-Troponin I Assay Matches Lab-Based Tests

March 10, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Choosing a DOAC? Apixaban May Have an Edge Over Rivaroxaban

News Daily News

Choosing a DOAC? Apixaban May Have an Edge Over Rivaroxaban

March 09, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.